Mira Pharmaceuticals (MIRA) Cash & Equivalents (2022 - 2025)

Mira Pharmaceuticals has disclosed Cash & Equivalents across 4 years of filings, most recently posting $6.3 million for Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $6.3 million, up 124.04% year-over-year; the trailing twelve-month figure through Dec 2025 was $6.3 million (up 124.04% YoY), and the FY2025 annual result was $6.3 million, up 124.04% from the prior year.
• Cash & Equivalents came in at $6.3 million for Q4 2025 at Mira Pharmaceuticals, up from $2.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $6.3 million in Q4 2025 to a low of $1349.0 in Q1 2023.
• The 4-year median for Cash & Equivalents is $1.9 million (2025), against an average of $2.4 million.
• Across the five-year window, Cash & Equivalents tumbled 96.99% in 2023 and jumped 259351.45% in 2024, its largest moves.
• Mira Pharmaceuticals' Cash & Equivalents stood at $350978.0 in 2022, then soared by 1211.35% to $4.6 million in 2023, then sank by 38.45% to $2.8 million in 2024, then jumped by 124.04% to $6.3 million in 2025.
• The last three Cash & Equivalents figures came in at $6.3 million (Q4 2025), $2.6 million (Q3 2025), and $730475.0 (Q2 2025), per Business Quant data.